Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma

Journal of Clinical Oncology

Volumn 33, Issue 8, 2015, Pages 894-900

  Ren, ZhengGang ^a   Zhu, KangShun ^c   Kang, HaiYan ^e   Lu, MinQiang ^c   Qu, ZengQiang ^b   Lu, LiGong ^d   Song, TianQiang ^h   Zhou, WeiPing ^b   Wang, Hui ⁱ   Yang, WeiZhu ^j   Wang, Xuan ^k   Yang, YongPing ^f   Shi, LeHua ^b   Bai, YuXian ^l   Guo, XiaoFeng ^g   Ye, Sheng Long ^a  

^a FUDAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e 301 Military Hospital   (China)

^f 302 MILITARY HOSPITAL   (China)

^g Chinese Anti Cancer Association   (China)

^h KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

ⁱ Jilin Provincial Tumor Hospital   (China)

^j FUJIAN MEDICAL UNIVERSITY   (China)

^k Nanjing Liberation Army 81 Hospital   (China)

^l Heilongjiang Provincial Cancer Hospital   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; UNCLASSIFIED DRUG; UREA; UREA BASED CREAM; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; EMULSION; NICOTINAMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BEST SUPPORTIVE CARE; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FATIGUE; FEMALE; HAND FOOT SKIN REACTION; HEADACHE; HEALTH CARE; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN MANIFESTATION; THERAPY EFFECT; TREATMENT RESPONSE; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CHINA; COMPLICATION; DRUG EFFECTS; EMULSION; HAND-FOOT SYNDROME; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; RISK; SKIN; STATISTICAL MODEL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHINA; EMULSIONS; FEMALE; HAND-FOOT SYNDROME; HUMANS; INCIDENCE; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NIACINAMIDE; ODDS RATIO; PHENYLUREA COMPOUNDS; QUALITY OF LIFE; QUESTIONNAIRES; SKIN; TREATMENT OUTCOME; UREA; YOUNG ADULT;

EID: 84924903352     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.9651     Document Type: Article

References (34)

1. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
2. Wilhelm SM, Adnane L, Newell P, et al: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140, 2008
3. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858, 2006
4. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
5. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
6. Bruix J, Sherman M, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology 53:1020-1022, 2011
7. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 56:908-943, 2012
8. Verslype C, Rosmorduc O, Rougier P, et al: Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 56:vii41-vii48, 2012 (suppl 7)
9. Chinese Anti-Cancer Association Society of Liver Cancer, Chinese Society of Clinical Oncology, Chinese Society of Hepatology Liver Cancer Study Group: The expert consensus on the treatment standards for hepatocellular carcinoma. Dig Dis Endosc 3:40-51, 2009
10. Ministry of Health of the People's Republic of China: The diagnosis and treatment guideline of primary liver cancer (version 2011). Chin Clin Oncol 6:929-946, 2011
11. Song P, Tobe RG, Inagaki Y, et al: The management of hepatocellular carcinoma around the world: A comparison of guidelines from 2001 to 2011. Liver Int 32:1053-1063, 2012
12. Robert C, Soria JC, Spatz A, et al: Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491-500, 2005
13. Beldner M, Jacobson M, Burges GE, et al: Localized palmar-plantar epidermal hyperplasia: A previously undefined dermatologic toxicity to sorafenib. Oncologist 12:1178-1182, 2007
14. Lacouture ME, Reilly LM, Gerami P, et al: Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19:1955-1961, 2008
15. Yang CH, Lin WC, Chuang CK, et al: Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158:592-596, 2008
16. Zhang L, Zhou Q, Ma L, et al: Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol 36:344-350, 2011
17. Ogasawara S, Kanai F, Obi S, et al: Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 5:850-856, 2011
18. Kudo M, Imanaka K, Chida N, et al: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47:2117-2127, 2011
19. Porta C, Paglino C, Imarisio I, et al: Uncovering Pandora's vase: The growing problem of new toxicities from novel anticancer agents - The case of sorafenib and sunitinib. Clin Exp Med 7:127-134, 2007
20. Autier J, Escudier B, Wechsler J, et al: Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 144:886-892, 2008
21. Nardone B, Hensley JR, Kulik L, et al: The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 11: e61-e65, 2012
22. Hagemann I, Proksch E: Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol 76:353-356, 1996
23. Lacouture ME, Wu S, Robert C, et al: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13: 1001-1011, 2008
24. Anderson R, Jatoi A, Robert C, et al: Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 14:291-302, 2009
25. Anderson RT, Rajagopalan R: Development and\ validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 37:41-50, 1997
26. SAS Institute: SAS/STAT(R) User's Guide, Version 8. Cary, NC, SAS Institute, 1999
27. Dranitsaris G, Vincent MD, Yu J, et al: Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol 23:2103-2108, 2012
28. Manchen E, Robert C, Porta C: Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: Viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol 9:13-23, 20113
29. Robert C, Mateus C, Spatz A, et al: Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 50:299-305, 2009
30. Wood LS, Lemont H, Jatoi A, et al: Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncol 7:23-29, 2010
31. Duvic M, Asano AT, Hager C, et al: The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol 39:S129-S133, 1998
32. Scheithauer W, McKendrick J, Begbie S, et al: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 14:1735-1743, 2003
33. Chu D, Lacouture ME, Fillos T, et al: Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol 47:176-186, 2008
34. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006